Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Prenetics Holding Company Limited (PRENW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PRENW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -25% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.17 | 52 Weeks Range 0.01 - 0.05 | Updated Date 06/21/2025 |
52 Weeks Range 0.01 - 0.05 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -115.91% | Operating Margin (TTM) -61.41% |
Management Effectiveness
Return on Assets (TTM) -14.52% | Return on Equity (TTM) -28.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9154745 |
Shares Outstanding - | Shares Floating 9154745 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Prenetics Holding Company Limited
Company Overview
History and Background
Prenetics Holding Company Limited was founded in 2014. Initially focused on genetic testing, it has expanded into preventative and personalized healthcare through diagnostic and genetic testing. It gained prominence with its COVID-19 testing solutions and has since diversified its offerings.
Core Business Areas
- Genetic and Diagnostic Testing: Prenetics offers genetic testing for personalized healthcare insights and diagnostic testing for various diseases.
- COVID-19 Testing Solutions: Provides rapid and accurate COVID-19 testing services, including PCR and rapid antigen tests.
- Preventative Healthcare Programs: Offers comprehensive preventative healthcare programs based on genetic and lifestyle data.
Leadership and Structure
The leadership team includes key executives overseeing different business units. Organizational structure consists of various departments including R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- CircleDNA: CircleDNA is a comprehensive at-home DNA test providing insights into ancestry, health risks, diet, and fitness. Competitors include 23andMe (also listed), AncestryDNA, and MyHeritage DNA. Market share data is fragmented but estimates place CircleDNA as a smaller but growing player with the at-home genetic testing market. Revenue and user data is privately held.
- Competitors: 23andMe,AncestryDNA,MyHeritage DNA
- COVID-19 Testing Services: Provides COVID-19 testing services, including PCR and rapid antigen tests, contributing significantly to revenue in recent years but is now dwindling down as the pandemic is over. Competitors include Quest Diagnostics (DGX), LabCorp (LH), and numerous local testing labs.
- Competitors: Quest Diagnostics (DGX),LabCorp (LH)
Market Dynamics
Industry Overview
The genetic testing and diagnostic market is growing rapidly, driven by increasing awareness of personalized medicine, advancements in technology, and rising healthcare expenditure. The market for COVID-19 testing has substantially decreased and preventative health programs are expanding.
Positioning
Prenetics is positioned as a leader in personalized and preventative healthcare with focus on genomics and diagnostic testing. It's competitive advantages include its diverse product portfolio and brand recognition.
Total Addressable Market (TAM)
The global genetic testing market is projected to reach hundreds of billions of USD by 2030. Prenetics is strategically positioned with a mix of genetic testing and diagnostic services to capture a portion of this growing TAM.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diverse product portfolio
- Innovative technology
- Strategic partnerships
Weaknesses
- Limited profitability
- High operating expenses
- Reliance on COVID-19 testing revenue (decreasing)
- Small Market Share
Opportunities
- Expanding into new markets
- Developing new products and services
- Increasing adoption of personalized medicine
- Partnerships and acquisitions
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Evolving technology
Competitors and Market Share
Key Competitors
- 23andMe (Private)
- Myriad Genetics (MYGN)
- Exact Sciences (EXAS)
Competitive Landscape
Prenetics faces intense competition from established players in the genetic testing and diagnostics market. Its competitive advantage lies in its focused approach and diverse portfolio.
Growth Trajectory and Initiatives
Historical Growth: Growth in recent years was significantly boosted by COVID-19 testing, with now declining growth without reliance on these testing measures.
Future Projections: Projections indicate that future growth will be focused on preventative care. Analyst estimates are not consistently available.
Recent Initiatives: Recent initiatives include expanding into new markets, investing in R&D, and strengthening its partnerships.
Summary
Prenetics is a growing company in the preventative and diagnostic healthcare space that grew rapidly during the pandemic, but may have slowed down. They are working towards innovation in technology and they have a diverse portfolio, despite some competition and potential threats. It will have to manage competition and regulatory changes in this market to find future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Press releases
- Financial news sources
Disclaimers:
This analysis is based on available information and does not constitute financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prenetics Holding Company Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 285 | Website https://www.prenetics.com |
Full time employees 285 | Website https://www.prenetics.com | ||
Prenetics Global Limited, a consumer health company, focuses on empowering individuals to take control of their health through science-backed solutions in Hong Kong, Taiwan, the United States, and internationally. The company operates in three segments: Prevention, Diagnostics, and Consumer Health. It operates IM8 Health that sells health and wellness products; and provides fulfillment and distribution services for sports nutrition products under the Consumer Health segment. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions under Prevention segment.; and ACT Genomics that provides precision oncology testing services under the Diagnostics segment. In addition, it develops and commercializes multi-cancer early detection technologies. Further, the company offers a range of genomic profiling panels tailored for requirements and clinician needs. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.